p53-induced growth arrest is regulated by the mitochondrial SirT3 deacetylase.
A hallmark of p53 function is to regulate a transcriptional program in response to extracellular and intracellular stress that directs cell cycle arrest, apoptosis, and cellular senescence. Independent of the role of p53 in the nucleus, some of the anti-proliferative functions of p53 reside within the mitochondria [1]. p53 can arrest cell growth in response to mitochondrial p53 in an EJ bladder carcinoma cell environment that is naïve of p53 function until induced to express p53 [2]. TP53 can independently partition with endogenous nuclear and mitochondrial proteins consistent with the ability of p53 to enact senescence. In order to address the role of p53 in navigating cellular senescence through the mitochondria, we identified SirT3 to rescue EJ/p53 cells from induced p53-mediated growth arrest. Human SirT3 function appears coupled with p53 early during the initiation of p53 expression in the mitochondria by biochemical and cellular localization analysis. Our evidence suggests that SirT3 partially abrogates p53 activity to enact growth arrest and senescence. Additionally, we identified the chaperone protein BAG-2 in averting SirT3 targeting of p53 -mediated senescence. These studies identify a complex relationship between p53, SirT3, and chaperoning factor BAG-2 that may link the salvaging and quality assurance of the p53 protein for control of cellular fate independent of transcriptional activity.
Li
SiDe
S
Department of Pediatrics, Mount Sinai School of Medicine, New York, New York, United States of America.
Banck
Michaela
M
Mujtaba
Shiraz
S
Zhou
Ming-Ming
MM
Sugrue
Mary M
MM
Walsh
Martin J
MJ
D000107:Acetylation; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D016922:Cellular Senescence; D017353:Gene Deletion; D018840:HSP70 Heat-Shock Proteins / Q000378:metabolism; D006801:Humans; D008928:Mitochondria / Q000201:enzymology*; D018832:Molecular Chaperones; D009243:NAD / Q000378:metabolism; D010641:Phenotype; D011485:Protein Binding; D055550:Protein Stability; D017434:Protein Structure, Tertiary; D021381:Protein Transport; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D056566:Sirtuin 3 / Q000378:metabolism*; D013347:Subcellular Fractions / Q000201:enzymology; D016159:Tumor Suppressor Protein p53 / Q000737:chemistry / Q000378:metabolism*; D001749:Urinary Bladder Neoplasms / Q000473:pathology
C492980:BAG2 protein, human; D018840:HSP70 Heat-Shock Proteins; D018832:Molecular Chaperones; D019253:Proto-Oncogene Proteins c-bcl-2; D016159:Tumor Suppressor Protein p53; D009243:NAD; C466093:SIRT3 protein, human; D056566:Sirtuin 3
Mol Biol Cell. 2005 Dec;16(12):5891-900
16207813
EMBO J. 2004 Jun 16;23(12):2369-80
15152190
Science. 1999 Feb 19;283(5405):1129-30
10075573
Mol Biol Cell. 2005 Oct;16(10):4623-35
16079181
Nature. 2003 May 8;423(6936):181-5
12736687
Mol Cell Biol. 2008 Oct;28(20):6384-401
18710944
J Biol Chem. 1995 Mar 10;270(10):5289-98
7534293
J Biol Chem. 2005 Apr 8;280(14):13560-7
15653680
Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13653-8
12374852
Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10794-9
12960381
Cell Death Differ. 2006 Jun;13(6):941-50
16601750
Oncogene. 1999 Mar 25;18(12):2149-55
10321740
Cancer Gene Ther. 2000 Jan;7(1):4-12
10678350
J Biol Chem. 2000 May 26;275(21):16202-12
10821866
Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10230-10235
16790548
Cell Death Differ. 2005 Feb;12(2):197-200
15550936
J Biol Chem. 2006 Mar 31;281(13):8600-6
16443602
Cell. 2007 Oct 5;131(1):93-105
17923090
Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7166-71
10852958
Cell Cycle. 2007 Jul 15;6(14):1718-23
17630506
Proc Natl Acad Sci U S A. 1997 Sep 2;94(18):9648-53
9275177
Curr Opin Cell Biol. 2001 Apr;13(2):232-8
11248558
Genes Dev. 2007 Apr 15;21(8):920-8
17437997
Annu Rev Biochem. 2004;73:417-35
15189148
Curr Opin Genet Dev. 2001 Apr;11(2):189-98
11250143
Mol Cell. 2003 Mar;11(3):577-90
12667443
J Leukoc Biol. 2004 Jun;75(6):939-50
14742637
J Biol Chem. 2004 Nov 19;279(47):48836-45
15358769
Cell. 2001 Oct 19;107(2):137-48
11672522
Novartis Found Symp. 2004;259:197-205; discussion 205-7, 223-5
15171255
Nature. 2000 Feb 17;403(6771):795-800
10693811
Biochim Biophys Acta. 2004 Nov 29;1695(1-3):171-88
15571814
Oncogene. 2010 Feb 25;29(8):1155-66
19935715
Oncogene. 2004 Apr 12;23(16):2907-18
15077153
Cell Cycle. 2007 Nov 1;6(21):2669-77
17957139
EMBO Rep. 2001 Oct;2(10):885-90
11600451
EMBO J. 2007 Feb 21;26(4):923-34
17268548
Int J Biochem Cell Biol. 2005 May;37(5):961-76
15743671
EMBO J. 2003 Oct 15;22(20):5446-58
14532117
Cancer Res. 2005 Nov 1;65(21):9971-81
16267022
Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10224-10229
16788062
Mol Cell Biol. 2006 Jan;26(1):28-38
16354677
J Biol Chem. 1999 Mar 19;274(12):7803-15
10075672
Cytometry. 2001 Oct 1;45(2):83-6
11590619
Oncogene. 1999 May 6;18(18):2789-97
10362249
Exp Cell Res. 2001 May 1;265(2):262-73
11302691
Curr Opin Oncol. 2002 Jan;14(1):86-91
11790986
Curr Opin Cell Biol. 2005 Dec;17(6):631-6
16226451
Methods Mol Med. 2004;88:231-8
14634234
J Cell Biol. 2002 Aug 19;158(4):647-57
12186850
J Clin Invest. 2009 Sep;119(9):2758-71
19652361
Biochem Biophys Res Commun. 1999 Jul 22;261(1):123-30
10405334
Mol Cell. 2004 Oct 8;16(1):93-105
15469825
Oncogene. 2007 Aug 13;26(37):5505-20
17694090
J Biol Chem. 2007 Sep 28;282(39):28441-28454
17666403
Mol Cell Biol. 2007 Dec;27(24):8807-14
17923681
Stem Cells. 1999;17(4):226-32
10437986
EMBO J. 2002 May 15;21(10):2383-96
12006491
J Biol Chem. 2005 Jul 22;280(29):27443-8
15911628
Cell. 2007 Sep 21;130(6):1095-107
17889652